Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 17, 2013

 

 

Corcept Therapeutics Incorporated

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-50679   77-0487658

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

149 Commonwealth Drive

Menlo Park, CA 94025

(Address of principal executive offices, with zip code)

(650) 327-3270

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders

On May 17, 2013, we held our annual meeting of stockholders to consider and vote on proposals: 1) to elect directors to hold office until our annual meeting of stockholders in 2014 and until their successors are qualified and elected and 2) to ratify the appointment of Ernst & Young, LLP, as our independent registered public accounting firm for the fiscal year ending December 31, 2013.

A total of 99,814,250 shares of Corcept common stock held by stockholders of record at the close of business on April 10, 2013 were entitled to vote at the annual meeting. The total number of shares voted at the annual meeting was 92,765,109. The voting on the four matters is set forth below:

Proposal 1 – Election of Directors - The following directors were elected to serve until the 2014 annual meeting of stockholders and until their successors are elected and qualified.

 

     For      Withheld      Broker Non-Votes  

Director:

        

G. Leonard Baker, Jr.

     70,827,192         222,592         21,715,325   

Joseph K. Belanoff, M.D.

     70,822,877         226,907         21,715,325   

Daniel M. Bradbury

     70,865,811         183,973         21,715,325   

Joseph C. Cook, Jr.

     70,596,667         453,117         21,715,325   

Patrick G. Enright

     70,827,977         221,807         21,715,325   

David L. Mahoney

     70,902,921         146,863         21,715,325   

Joseph L. Turner

     70,907,621         142,163         21,715,325   

James N. Wilson

     62,667,942         8,381,842         21,715,325   

Proposal 2 – To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2013.

 

For

     92,126,210   

Against

     481,424   

Abstain

     157,475   

Broker Non-Votes

     N/A   

 

-2-


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CORCEPT THERAPEUTICS INCORPORATED
Date: May 21, 2013     By:  

/s/ G. Charles Robb

      G. Charles Robb
      Chief Financial Officer

 

-3-